X-Cell Says Estradiol May Offer Greater Restenotic Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Estrogen-based anti-restenotic drug could accelerate healing and have lower rates of stent thrombosis than J&J's Cypher and Boston Scientific's Taxus, according to the firm.
You may also be interested in...
J&J Sues Boston Scientific, Abbott For $5.5 Bil For Breach Of Contract
After losing bidding war for Guidant, J&J charges winning firms with using leaked information.
State Drug Advertising Laws Foreshadow Future Device Regulation
Some state lawmakers contend that industry's voluntary code of ethics is insufficient, according to Kyphon's chief compliance officer.
FDA Official Distinguishes Scientific Exchange From Off-Label Promotion
Agency compliance head Tim Ulatowski says he's not concerned about the scientific exchange of information on products.